Our data suggest that vimentin‐dependent cMet activation is independent of canonical mechanisms of cMet activation because a HGF neutralizing antibody can still affect cMet activation in mesenchymal NSCLC and because robust cMet activation by an activating mutation or amplification was not affected by Plk1 inhibition. The gene discussed is MET; the disease is non-small cell lung carcinoma.